Desferasirox
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Iron Overload
Conditions
Iron Overload
Trial Timeline
Oct 1, 2011 โ Nov 1, 2013
NCT ID
NCT01546415About Desferasirox
Desferasirox is a approved stage product being developed by Novartis for Iron Overload. The current trial status is completed. This product is registered under clinical trial identifier NCT01546415. Target conditions include Iron Overload.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01546415 | Approved | Completed |
Competing Products
20 competing products in Iron Overload
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KER-047 | Keros Therapeutics | Phase 2 | 44 |
| H. pylori treatment | Eisai | Phase 2/3 | 65 |
| Deferasirox | Novartis | Phase 3 | 77 |
| CSJ137 + Placebo | Novartis | Phase 1 | 33 |
| Deferasirox and Deferoxamine | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 2 | 52 |
| ICL670 | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Deferasirox + Deferasirox | Novartis | Phase 2/3 | 65 |
| Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Deferasirox dispersible tablet + Defearisox film-coated tablet | Novartis | Phase 2 | 52 |
| deferasirox | Novartis | Approved | 85 |
| Deferasirox (ICL670) | Novartis | Phase 1/2 | 41 |
| ICL670 | Novartis | Approved | 85 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Z-213 + Saccharated Ferric Oxide | Zeria Pharmaceutical | Phase 3 | 76 |
| Z-213 | Zeria Pharmaceutical | Phase 3 | 76 |